ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "AcelRx Pharmaceuticals, Inc." (ACRX) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"AcelRx Pharmaceuticals, Inc." (ACRX)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Pharmaceuticals
Competitors: MNK, IMMY, HSP, RDY

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: C down no change
Last Week: C same upgrade
Two Weeks Ago: D up downgrade
service keys

"AcelRx Pharmaceuticals, Inc."© quotemedia

Company Profile

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company is developing its lead product candidate, ARX-01, which is a Sufentanil NanoTab PCA system that is in Phase III clinical trials for acute post-operative pain. Its product candidates that have completed Phase II clinical trials comprise ARX-02, a Sufentanil NanoTab BTP management system for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. Its product candidate under development also includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. AcelRx Pharmaceuticals, Inc. was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. The company was founded in 2005 and is based in Redwood City, California.

Recent News: "AcelRx Pharmaceuticals, Inc."